Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANEE MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1760411326
CMS profile
170140
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$917.82

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $917.82 20

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANEE MEHRA

NPI 1760411326 · CMS profile ID 170140

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $917.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $30.2112/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012013373 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.2012/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000690211 CMS
Novartis Pharmaceuticals Corporation $23.8311/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992949747 CMS
AstraZeneca Pharmaceuticals LP $26.4011/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014760893 CMS
SANOFI-AVENTIS U.S. LLC $20.7511/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050172407 CMS
Merck Sharp & Dohme LLC $20.2610/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048256285 CMS
Novartis Pharmaceuticals Corporation $21.7708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992949737 CMS
Novartis Pharmaceuticals Corporation $21.3008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992949739 CMS
Foundation Medicine, Inc. $18.6208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058792179 CMS
Merck Sharp & Dohme LLC $15.2907/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048256287 CMS
Coherus Biosciences Inc. $26.4807/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060244929 CMS
E.R. Squibb & Sons, L.L.C. $125.0006/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015008231 CMS
Genmab U.S., Inc. $92.4606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051347523 CMS
AVEO Pharmaceuticals, Inc. $238.1806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049064607 CMS
Mirati Therapeutics, Inc. $111.6205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057997417 CMS
Exelixis Inc. $25.8204/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044543137 CMS
Incyte Corporation $14.4503/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044505163 CMS
ARRAY BIOPHARMA INC $24.0703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049673369 CMS
Merck Sharp & Dohme LLC $21.2903/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048256283 CMS
PFIZER INC. $24.8203/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049480231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,242.50 5
PY2022 $4,211.09 5
PY2023 $917.82 20
PY2024 $2,617.99 14
PY2025 $273.81 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,124,333.75 93
PY2024 Principal investigator $813,892.28 61
PY2023 Principal investigator $633,471.41 125
PY2022 Principal investigator $830,697.81 139
PY2021 Recipient $330.00 1
PY2021 Principal investigator $979,164.73 91
PY2020 Principal investigator $622,730.93 67
PY2019 Principal investigator $214,554.45 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $17,540.72 12/31/2025 Non-covered Recipient Entity
University of Maryland
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1232926441
Principal investigator 1 Merck Sharp & Dohme LLC $10,300.50 12/31/2025 Non-covered Recipient Entity
University of Maryland Greenebaum Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232939901
Principal investigator 1 Janssen Research & Development, LLC $19,460.00 12/22/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383311
Principal investigator 1 Aveo Pharmaceuticals, Inc. $312.45 12/19/2025 Non-covered Recipient Entity
State of Maryland
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $640.71 12/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272225
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,006.15 12/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272223
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,025.50 12/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272221
Principal investigator 1 Coherus Oncology, Inc. $45,039.40 12/05/2025 Non-covered Recipient Entity
State of Maryland
SRF114-101 No dispute reported 06/30/2026 1235252433
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,111.40 12/05/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252498491
Principal investigator 1 Iovance Biotherapeutics, Inc. $26,146.90 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252498601
Principal investigator 1 Merck Sharp & Dohme LLC $11,740.40 11/24/2025 Non-covered Recipient Entity
University of Maryland
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1232926439
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,534.30 11/18/2025 Non-covered Recipient Entity
State of Maryland
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911685
Principal investigator 1 Iovance Biotherapeutics, Inc. $975.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252498589
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,726.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252498591
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,560.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252498593
Principal investigator 1 Janssen Research & Development, LLC $8,832.00 11/10/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383403
Principal investigator 1 Merck Sharp & Dohme LLC $16,435.00 11/06/2025 Non-covered Recipient Entity
University of Maryland Greenebaum Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232939899
Principal investigator 1 Merck Sharp & Dohme LLC $34,020.00 10/14/2025 Non-covered Recipient Entity
University of Maryland Medical Group
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1232935791
Principal investigator 1 Iovance Biotherapeutics, Inc. $25,351.30 10/08/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252498597
Principal investigator 1 Aveo Pharmaceuticals, Inc. $15,602.58 10/06/2025 Non-covered Recipient Entity
State of Maryland
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911683
Principal investigator 1 Janssen Research & Development, LLC $12,538.00 10/06/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383361
Principal investigator 1 Iovance Biotherapeutics, Inc. $30,940.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252498595
Principal investigator 1 Iovance Biotherapeutics, Inc. $650.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252498599
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,625.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252498603
Principal investigator 1 Iovance Biotherapeutics, Inc. $241.80 09/26/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252497871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,092.00 09/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272219
Principal investigator 1 Janssen Research & Development, LLC $530.00 09/15/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383116
Principal investigator 1 Janssen Research & Development, LLC $4,573.00 09/15/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383438
Principal investigator 1 Incyte Corporation $4,964.75 09/11/2025 Non-covered Recipient Entity
U OF MARYLAND - GREENEBAUM CANCER CTR
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240609165
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,529.76 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272217
Principal investigator 1 Janssen Research & Development, LLC $27,859.55 09/08/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $528.53 09/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272215
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,656.25 08/15/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252497695
Principal investigator 1 Janssen Research & Development, LLC $6,933.00 08/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383296
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $640.71 08/13/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272213
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,693.44 08/04/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911665
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $259.76 08/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272211
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,269.10 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272203
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,807.30 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272205
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $599.20 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272207
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,269.10 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,092.00 07/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272201
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $599.20 07/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272197
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,345.50 07/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272199
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,050.00 07/21/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911659
Principal investigator 1 Iovance Biotherapeutics, Inc. $35,303.14 07/16/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252497867
Principal investigator 1 Iovance Biotherapeutics, Inc. $56,764.82 07/16/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252497869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,198.06 07/15/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272195
Principal investigator 1 Aveo Pharmaceuticals, Inc. $8,595.97 07/14/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911661
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,342.78 07/07/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911667
Principal investigator 1 PFIZER INC. $5,504.80 07/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228840922
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,050.00 06/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272191
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,179.10 06/18/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911675
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,281.42 06/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272189
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,868.00 06/13/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496065
Principal investigator 1 Iovance Biotherapeutics, Inc. $7,907.15 06/11/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252496207
Principal investigator 1 Janssen Research & Development, LLC $6,923.00 06/09/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383108
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,050.00 06/05/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911669
Principal investigator 1 Amgen Inc. $363,420.48 06/03/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND MEDICAL CENTER
Expanded Access request for Tarlatamab to treat a 45 y.o. Female Patient with DLL3+ High grade Neuroendocrine Tumor of the Lung No dispute reported 06/30/2026 1246650444
Principal investigator 1 Iovance Biotherapeutics, Inc. $12,666.00 06/02/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496195
Principal investigator 1 PFIZER INC. $32,233.60 06/02/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228845979
Principal investigator 1 PFIZER INC. $1,708.00 06/02/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228846077
Principal investigator 1 Iovance Biotherapeutics, Inc. $38.25 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252495877
Principal investigator 1 Iovance Biotherapeutics, Inc. $780.00 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496201
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,145.00 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496203
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,041.00 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496205
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,041.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252496209
Principal investigator 1 Iovance Biotherapeutics, Inc. $585.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252496211
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,080.70 05/12/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911677
Principal investigator 1 Janssen Research & Development, LLC $4,950.00 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,140.61 04/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272183
Principal investigator 1 Iovance Biotherapeutics, Inc. $21,411.10 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252495879
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,595.61 04/16/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911671
Principal investigator 1 Aveo Pharmaceuticals, Inc. $490.14 04/11/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911673
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $871.13 04/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272181
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,755.00 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496197
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,726.00 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 03/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272175
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,003.72 03/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272173
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,571.68 03/04/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911681
Principal investigator 1 Incyte Corporation $5,529.50 02/27/2025 Non-covered Recipient Entity
U OF MARYLAND - GREENEBAUM CANCER CTR
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240609168
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,448.32 02/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272171
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,856.00 02/21/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496461
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,111.00 02/21/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496597
Principal investigator 1 Iovance Biotherapeutics, Inc. $23,394.00 02/21/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496599
Principal investigator 1 Janssen Research & Development, LLC $41,736.00 02/17/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1175383344
Principal investigator 1 Iovance Biotherapeutics, Inc. $826.20 02/12/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
101623 No dispute reported 06/30/2026 1252496341
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,950.00 01/29/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
81990 No dispute reported 06/30/2026 1252496463
Principal investigator 1 Amgen Inc. $2,539.93 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND MEDICAL CENTER
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1246650432
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,525.74 01/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272163
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,525.74 01/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MARYLAND MED SYS
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272165
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,187.80 01/07/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911663
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,708.00 01/07/2025 Non-covered Recipient Entity
State of Maryland
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911679